M&G Investment Management Ltd. Boosts Stake in Humana Inc. (NYSE:HUM)

M&G Investment Management Ltd. lifted its holdings in Humana Inc. (NYSE:HUM) by 68.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,881 shares of the insurance provider’s stock after purchasing an additional 6,065 shares during the quarter. M&G Investment Management Ltd.’s holdings in Humana were worth $6,235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Humana by 3.2% in the first quarter. BlackRock Inc. now owns 12,352,180 shares of the insurance provider’s stock worth $5,178,651,000 after purchasing an additional 385,141 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Humana by 7.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,989,308 shares of the insurance provider’s stock valued at $4,098,313,000 after acquiring an additional 656,606 shares during the last quarter. FMR LLC increased its position in Humana by 14.0% during the fourth quarter. FMR LLC now owns 9,267,673 shares of the insurance provider’s stock valued at $3,802,248,000 after acquiring an additional 1,136,161 shares during the last quarter. Norges Bank purchased a new stake in Humana during the fourth quarter valued at $601,429,000. Finally, Newport Trust Co increased its position in Humana by 1.4% during the first quarter. Newport Trust Co now owns 1,464,234 shares of the insurance provider’s stock valued at $613,880,000 after acquiring an additional 20,452 shares during the last quarter. Hedge funds and other institutional investors own 92.11% of the company’s stock.

NYSE HUM opened at $420.96 on Friday. The company has a market capitalization of $54.31 billion, a price-to-earnings ratio of 14.97, a price-to-earnings-growth ratio of 1.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.67 and a current ratio of 1.67. The stock has a 50-day simple moving average of $437.99. Humana Inc. has a twelve month low of $365.06 and a twelve month high of $475.44.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 28th. The insurance provider reported $7.67 earnings per share for the quarter, topping analysts’ consensus estimates of $7.21 by $0.46. The firm had revenue of $20.67 billion during the quarter, compared to analyst estimates of $20.42 billion. Humana had a return on equity of 19.08% and a net margin of 4.72%. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.40 earnings per share. On average, sell-side analysts forecast that Humana Inc. will post 21.64 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 30th. Stockholders of record on Wednesday, June 30th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.67%. The ex-dividend date is Tuesday, June 29th. Humana’s dividend payout ratio (DPR) is 14.93%.

HUM has been the subject of a number of research reports. Mizuho upped their price objective on Humana from $462.00 to $480.00 and gave the company a “buy” rating in a research report on Thursday, April 29th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating and set a $447.00 price objective for the company. in a research report on Tuesday, March 30th. Oppenheimer upped their price objective on Humana from $460.00 to $480.00 and gave the company an “outperform” rating in a research report on Thursday, April 29th. Wells Fargo & Company began coverage on Humana in a report on Monday, May 24th. They set an “equal weight” rating and a $472.00 price target for the company. Finally, Citigroup boosted their price target on Humana from $496.00 to $510.00 in a report on Thursday, April 29th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $469.00.

In related news, insider Timothy Alan Wheatley sold 8,508 shares of the business’s stock in a transaction dated Monday, May 3rd. The stock was sold at an average price of $450.59, for a total value of $3,833,619.72. Following the sale, the insider now directly owns 11,494 shares in the company, valued at $5,179,081.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher H. Hunter sold 5,156 shares of the business’s stock in a transaction dated Thursday, April 29th. The stock was sold at an average price of $443.76, for a total value of $2,288,026.56. Following the completion of the sale, the insider now owns 8,653 shares in the company, valued at $3,839,855.28. The disclosure for this sale can be found here. 0.40% of the stock is currently owned by insiders.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Article: Stock Symbol

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.